Journal of Psychopharmacology

Article	Citations
The dosing procedure that “makes the poison”: Comparing the effects of single versus cumulative alcohol administration methods on emotion recognition	270
Which are the demographic and clinical characteristics of patients who respond to subcutaneous esketamine?	192
Science, safety and education: Informing the psychedelic treatment of psychiatric disorders	111
Off the RADAR; questions regarding the trial protocol of a randomised controlled trial of antipsychotic reduction and discontinuation	101
Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study	75
Glutamate levels across deep brain structures in patients with a psychotic disorder and its relation to cognitive functioning	74
The chronic effects of a combination of herbal extracts (Euphytose®) on psychological mood state and response to a laboratory stressor: A randomised, placebo-controlled, double blind study	66
Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat	59
Circadian rhythmicity in prepulse inhibition of the acoustic startle response: A study of chronotype and time-of-day effects in young healthy adults	57
Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study	56
The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies	56
Relationship between depression, prefrontal creatine and grey matter volume	49
Cannabimimetic and discriminative stimulus effects of hexahydrocannabinols in mice	49
Psychedelics and the ‘inner healer’: Myth or mechanism?	45
Effectiveness of vortioxetine in elderly patients with major depressive disorder in real-world clinical practice: Results from the RELIEVE study	44
Co-use of psychedelics with other substances: Findings from the global psychedelic survey	44
Perceptions of safety, subjective effects, and beliefs about the clinical utility of lysergic acid diethylamide in healthy participants within a novel intervention paradigm: Qualitative results from a	42
Relationship between change in social evaluation learning and mood in early antidepressant treatment: A prospective cohort study in primary care	40
Associations between regular cannabis use and brain resting-state functional connectivity in adolescents and adults	40
The D1/D2-like receptor antagonist flupentixol and the D2-like receptor antagonist L-741626 decrease operant responding for nicotine and food and locomotor activity in male and female rats	37
Effects of 31 recombinant CYP2C19 variants on clomipramine metabolism in vitro	36
An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine	36
The Journal of Psychopharmacology: La Plus ça change. . .	36
Repurposing psychopharmacology: A two-way street?	34
Pharmaco-fUS in cognitive impairment: Lessons from a preclinical model	33

Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration–effect relations using the IB-de-risk tool	33
A framework for assessment of adverse events occurring in psychedelic-assisted therapies	33
A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapy	33
Voluntary nicotine consumption and reward in a subset of diversity outbred founder strains	32
Ketamine use in a large global sample: Characteristics, patterns of use and emergency medical treatment	32
Impaired discrimination of a subanesthetic dose of ketamine in a maternal immune activation model of schizophrenia risk	30
Not too quick on “Debunking the myth of ‘Blue Mondays’”	30
Serotonin release by parachloroamphetamine in rats with high and low sociability: High prefrontal release capacity in sociable females	28
Haloperidol dopamine receptor occupancy and antagonism correspond to delirium agitation scores and EPS risk: A PBPK-PD modeling analysis	27
The 5-HT1A receptor biased agonists, NLX-204 and NLX-101, like ketamine, elicit rapid-acting antidepressant activity in the rat chronic mild stress model via cortical mechanisms	27
What are set and setting: Reducing vagueness to improve research and clinical practice	26
Corrigendum: Is psychedelic use associated with cancer? Interrogating a half-century-old claim using contemporary population-level data	26
Postpartum depression: A role for psychedelics?	25
The New Zealand drug harms ranking study: A multi-criteria decision analysis	25
Elevated C-reactive protein among symptomatic youth with bipolar disorder	24
A phase 1b study to investigate the potential interactions between ASP8062 and buprenorphine/naloxone in patients with opioid use disorder	23
Impact of psychedelics on craving in addiction: A systematic review	23
Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study	23
Wistar Kyoto rats exhibit decreased serotonin neuronal firing and increased norepinephrine burst activity but dampened hippocampal α2-adrenoceptor sensitivity	23
Altered amygdala-cortical connectivity in individuals with Cannabis use disorder	22
A randomised double-blind, placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression (the PAX-BD study)	22
Increasing dietary choline attenuates spatial memory deficits resulting from exposure to the chemotherapeutic agents cyclophosphamide and doxorubicin	22
Drug–drug interactions involving classic psychedelics: A systematic review	21
The mechanism of action of clozapine	21
Oral esketamine for patients with severe treatment-resistant depression: Effectiveness, safety, and tolerability of a six-week open-label treatment program	20
Hippocampal phase precession is preserved under ketamine, but the range of precession across a theta cycle is reduced	20
Efficacy of antidepressant drugs in the treatment of depression in Alzheimer disease patients: A systematic review and network meta-analysis	20
The low risk for early renal damage during lithium treatment has not changed over time	20
Psychedelic-assisted psychotherapy: The need to monitor adverse events	20
Associations of antidepressants and antipsychotics with lipid parameters: Do CYP2C19/CYP2D6 genes play a role? A UK population-based study	20
Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors	19
Impact of drug-induced Parkinsonism and tardive dyskinesia on health-related quality of life in schizophrenia	19
Insufficiency of ventral hippocampus to medial prefrontal cortex transmission explains antidepressant non-response	18
Associations between paraoxonase-1 activity and therapeutic drug monitoring indicators in schizophrenia patients treated with olanzapine: A cross-sectional study	18
Evaluation of the sedative-motor effects of novel GABAkine imidazodiazepines using quantitative observation techniques in rhesus monkeys	18
Evidence-based guidelines for the interpretation of the 9-item Concise Health Risk Tracking – Self-Report (CHRT-SR9) measure of suicidal risk	18
Prospects for new drugs to treat binge-eating disorder: Insights from psychopathology and neuropharmacology	17
The antidepressant effect and safety of non-intranasal esketamine: A systematic review	17
Association of clozapine treatment and rate of methamphetamine or amphetamine relapses and abstinence among individuals with concurrent schizophrenia spectrum and amphetamine use disorder: A retrospec	17
A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression	17
Effect of CannEpil® on simulated driving performance and co-monitoring of ocular activity: A randomised controlled trial	17
The effects of reserpine on depression: A systematic review	16
Neuropsychological performance in young adults with cannabis use disorder	16
Blackcurrant ( Ribes nigrum L.) improves cholinergic signaling and protects against chronic Scopolamine-induced memory impairment in mice	16
Validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview among outpatients with schizophrenia	16
Older adults in psychedelic-assisted therapy trials: A systematic review	16
The effects of selective serotonin reuptake inhibitors on memory functioning in older adults: A systematic literature review	16
Psilocybin for clinical indications: A scoping review	16
Associations between MDMA/ecstasy use and physical health in a U.S. population-based survey sample	16
Pivotal role of orexin signaling in the posterior paraventricular nucleus of the thalamus during the stress-induced reinstatement of oxycodone-seeking behavior	16

Is lack of goal-conflict-specific rhythmicity a biomarker for treatment resistance in generalised anxiety but not social anxiety or major depression?	16
Differences in social brain function in autism spectrum disorder are linked to the serotonin transporter: A randomised placebo-controlled single-dose crossover trial	15
Examining the role of systemic chronic inflammation in diet and sleep relationship	15
Comparative safety of chronic versus intermittent benzodiazepine prescribing in older adults: A population-based cohort study	15
Chronic Cannabis users exhibit altered oscillatory dynamics and functional connectivity serving visuospatial processing	15
Modafinil: A closer look at its theoretical toxicological potential	15
Mechanisms of psilocybin on the treatment of posttraumatic stress disorder	15
A three-stage strategy for conducting an experimental investigation: A recommendation to improve the reproducibility of reported conclusions	15
Episodic foresight is impaired following acute alcohol intoxication	14
Efficacy and safety of supraphysiologic doses of levothyroxine for patients with bipolar depression in adults: A systematic review	14
A letter to the editor, associated with the article entitled “Efficacy and tolerability of combination treatments for major depression: Antidepressants plus second-generation antipsychotics vs esketam	14
Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research	14
Revisiting monoamine oxidase inhibitors: A potential dual-action therapy for patients with prostate cancer and comorbid depression?	14
Exploring the efficacy and safety of a novel standardized ashwagandha (Withania somnifera) root extract (Witholytin®) in adults experiencing high stress and fatigue in a randomized, double-blin	14
We need to talk: The urgent conversation on chronic pain, mental health, prescribing patterns and the opioid crisis	13
Amphetamine use disorder is associated with striatum hypoactivation during anticipation of loss and reward	13
Common protein networks for various drug regimens of major depression are associated with complement and immunity	13
The CannTeen Study: Cannabis use disorder, depression, anxiety, and psychotic-like symptoms in adolescent and adult cannabis users and age-matched controls	13
Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD)	13
Just a gut feeling: Faecal microbiota transplant for treatment of depression – A mini-review	13
Temporal profile of intranasal oxytocin in the human autonomic nervous system at rest: An electrocardiography and pupillometry study	13
Significance of mammalian N, N-dimethyltryptamine (DMT): A 60-year-old debate	13
Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study	13
The association between N-methyl-d-aspartate receptor availability and glutamate levels: A multi-modal PET-MR brain imaging study in first-episode psychosis and healthy controls	13
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up	13
Recasting the role of electroconvulsive therapy and the electroconvulsive therapy practitioner: For severe illness, not necessarily treatment-resistant depression	12
Aberrant inhibitory processing in the somatosensory cortices of cannabis-users	12
The psychedelic effects of cannabis: A review of the literature	12
Younger, drunk, and fast: Paradoxical rapid reaction time in hazardous drinkers	12
Pictorial representation of illness and self measure (PRISM): A putative transdiagnostic tool for evaluating therapeutic effects of psychedelic treatments	12
Causes, clinical characteristics, and outcomes of high lithium levels and intoxications: Retrospective analysis of patient records	11
Tripping into the unknown: Exploring the experiences of first-time LSD users through global drug survey insights	11
The interaction between kynurenine pathway, suicidal ideation and augmentation therapy with minocycline in patients with treatment-resistant depression	11
Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020	11
Effect of selective serotonin reuptake inhibitor discontinuation on anxiety-like behaviours in mice	11
Intoxication without anticipation: Disentangling pharmacological from expected effects of alcohol	11
Effects of CYP2D6*4 polymorphism on the steady-state concentration of paroxetine in patients diagnosed with depressive episode and comorbid alcohol use disorder	11
A transdiagnostic systematic review and meta-analysis of ketamine’s anxiolytic effects	11
Is there a risk of addiction to ketamine during the treatment of depression? A systematic review of available literature	11
Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium	11
Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression	11
Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth	11
The psychopharmacology of mood disorders	11
Sub-anesthetic doses of ketamine increase single cell entrainment in the rat auditory cortex during auditory steady-state response	11
No evidence that post-training dopamine D2 receptor agonism affects fear generalization in male rats	11
Ketamine: A new chapter for clinical psychopharmacology?	11
Role of serotonin in modulation of decision-making in Parkinson’s disease	11
Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database	11
Clinical correlates of early onset antipsychotic treatment resistance	10
Mapping acute alcohol effects on bodily sensations: A cross-dimensional interoceptive approach	10
Deaths from novel psychoactive substances in England, Wales and Northern Ireland: Evaluating the impact of the UK psychoactive substances act 2016	10
Increasing recreational nitrous oxide use: Should we worry? A narrative review	10
Common pitfalls, and how to avoid them, in child and adolescent psychopharmacology: Part I	10
Hemispheric annealing and lateralization under psychedelics (HEALS): A novel hypothesis of psychedelic action in the brain	10
Effects of clozapine treatment on the improvement of substance use disorders other than nicotine in individuals with schizophrenia spectrum disorders: A systematic review and meta-analysis	10
Effects of acute lysergic acid diethylamide on intermittent ethanol and sucrose drinking and intracranial self-stimulation in C57BL/6 mice	10
Escitalopram should be investigated in anorexia nervosa: Rationale and review of mechanisms	10
Naturalistic use of psychedelics is related to emotional reactivity and self-consciousness: The mediating role of ego-dissolution and mystical experiences	10
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science	10
The efficacy of vortioxetine in the acute treatment of major depressive disorder: A systematic review and meta-analysis	9
Development of the Protective Strategies for Psychedelics Scale: A novel inventory to assess safety strategies in the context of psychedelics	9
Effect of ashwagandha ( Withania somnifera ) extract with Sominone (Somin-On™) to improve memory in adults with mild cognitive impairment: A randomized, double-blind, pl	9
Psilocybin history, action and reaction: A narrative clinical review	9
Role of α1-GABAA receptors in the serotonergic dorsal raphe nucleus in models of opioid reward, anxiety, and depression	9
Co-medication with disulfiram markedly increased serum clozapine levels: Two case reports	9
Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review	9
Exploring the impact of MDMA and oxytocin ligands on anxiety and social responses: A comprehensive behavioural and molecular study in the zebrafish model	9
Hippocampal and parahippocampal volume and function predict antidepressant response in patients with major depression: A multimodal neuroimaging study	9
Transgenerational evidence of increases in dopamine D2 receptor sensitivity in rodents: Impact on sensorimotor gating, the behavioral response to nicotine and BDNF	9
Monoamine neurotransmitter-related gene-based genome-wide association study of low-dose ketamine in patients with treatment-resistant depression	9
Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression	9
Higher orexin-A levels are associated with treatment response to clozapine in patients with schizophrenia: A cross-sectional study	8
Severe neutropenia unrelated to clozapine in patients receiving clozapine	8
A narrative synthesis of research with 5-MeO-DMT	8
Award winning abstracts presented at the 14th Annual International College of Mental Health Pharmacy (CMHP) Conference Glasgow, UK, on 11th and 12th October 2024	8
Accuracy in recognising happy facial expressions is associated with antidepressant response to a NOP receptor antagonist but not placebo treatment	8
Comparative efficacy of quetiapine by dose and formulation for psychosis in schizophrenia: A systematic review and dose–response model-based network meta-analysis	8
Fluoxetine rescues the depressive-like behaviour induced by reserpine and the altered emotional behaviour induced by nicotine withdrawal in zebrafish: Involvement of tyrosine hydroxylase	8
Influence of panic disorder and paroxetine on brain functional hubs in drug-free patients	8
Can pediatric bipolar disorder be successfully treated when comorbid with conduct disorder? A secondary analysis of clinical trials of risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazol	8

Commentary on Cochrane review: “Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder”	8
Metformin efficacy and safety as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double-blind, placebo-controlled trial	8
Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview	8
Influence of GABAA and GABAB receptor activation on auditory sensory gating and its association with anxiety in healthy volunteers	8
Antipsychotic polypharmacy and high-dose antipsychotic therapy compared to antipsychotic monotherapy at standard doses in schizophrenia – a systematic review	8
Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms	7
Harnessing placebo: Lessons from psychedelic science	7
Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension	7
Clozapine rechallenge or continuation despite neutropenia or agranulocytosis using colony-stimulating factor: A systematic review	7
The pseudoscience of lithium and suicide: Reanalysis of a misleading meta-analysis	7
Impact of patient-specific factors on clozapine metabolism in individuals with treatment-resistant schizophrenia or schizoaffective disorder	7
The effect of first- and second-generation antipsychotics on brain morphology in schizophrenia: A systematic review of longitudinal magnetic resonance studies with a randomized allocation to treatment	7
Long-read sequencing of CYP2D6 may improve psychotropic prescribing and treatment outcomes: A systematic review and meta-analysis	7
Patient perspectives of lithium and quetiapine augmentation treatment in treatment-resistant depression: A qualitative assessment	7
Reduced attentional lapses in male rats following a combination treatment of low-dose D-serine and atomoxetine	7
Characteristics of poisonings involving ketamine in the United States, 2019–2021	7
Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study	7
Associations of treatment with hypnotics with suicide and attempted suicide: A nationwide cohort study	7
Exploring clozapine use in severe psychiatric symptoms associated with autism spectrum disorder: A scoping review	7
Individual differences in cocaine-induced conditioned place preference in male rats: Behavioral and transcriptomic evidence	7
Effects of gamma-aminobutyric acid on working memory and attention: A randomized, double-blinded, placebo-controlled, crossover trial	6
Habitual caffeine intake, genetics and cognitive performance	6
Do antipsychotic drugs shrink the brain? Probably not	6
Pharmacokinetics and pharmacodynamics of sublingual microdosed lysergic acid diethylamide in healthy adult volunteers	6
Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis	6
Cell-based serum anticholinergic activity assay and working memory in cognitively healthy older adults before and after scopolamine: An exploratory study	6
MDMA enhances positive affective responses to social feedback	6
Effects of benzodiazepine and orexin receptor antagonist on cognitive function revealed by auditory event-related potentials	6
Impaired face symmetry detection under alcohol, but no ‘beer goggles’ effect	6
Catalyst for change: Psilocybin’s antidepressant mechanisms—A systematic review	6
Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response	6
Utility of a controlled amphetamine withdrawal paradigm among adults who use methamphetamine: A pilot clinical trial	6
Abuse potential assessment of the dual orexin receptor antagonist daridorexant in rats	6
Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: An international, multicenter, randomized, double-blind, placebo-controlled trial	5
A phase 1 randomized, placebo-controlled study to investigate potential interactions between ASP8062, a positive allosteric modulator of the GABAB receptor, and morphine in recreational opi	5
Oral sodium oxybate does not alter plasma kisspeptin levels in healthy male volunteers	5
Hyperdopaminergia in rats is associated with reverse effort-cost dependent performance	5
Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes	5
CYP1A2 genotype-dependent effects of smoking on mirtazapine serum concentrations	5
Subchronic PCP effects on DNA methylation and protein expression of NMDA receptor subunit genes in the prefrontal cortex and hippocampus of female rats	5
Impact of childhood adversity on acute subjective effects of stimulant and opioid drugs: Evidence from placebo-controlled studies in healthy volunteers	5
A phase 1 study to assess potential interaction between ASP8062 and alcohol in healthy adult subjects	5
Clinical effects of CYP2D6 phenoconversion in patients with psychosis	5
Ketamine for refractory depression: Save the best for last?	5
The relationship between Parkinson’s disease and sexual hyperactivity secondary to drug treatment: A systematic review	5
Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes	5
Award winning abstracts presented at the 12th Annual International College of Mental Health Pharmacy (CMHP) Conference, Northampton, UK on 7th and 8th October 2022	5
Clozapine and the aryl hydrocarbon receptor	5
Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study	5
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease	5
Peri-traumatic consumption of classic psychedelics is associated with lower anxiety and post-traumatic responses 3 weeks after exposure	5
Combining bioinformatics, network pharmacology and artificial intelligence to predict the target genes of S-ketamine for treating major depressive disorder	5
Is psychedelic use associated with cancer?: Interrogating a half-century-old claim using contemporary population-level data	4
Common pitfalls, and how to avoid them, in child and adolescent psychopharmacology: Part II	4
ICPN meeting abstracts	4
Psychiatric risks for worsened mental health after psychedelic use	4
The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients	4
Dose of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding in older adults	4
Ketamine-induced changes in resting state connectivity, 2 h after the drug administration in patients with remitted depression	4
Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review	4
Award winning abstracts presented at The 11th Annual International College of Mental Health Pharmacy (CMHP) Conference. Manchester, UK on 8th and 9th October 2021	4
Debunking the myth of ‘Blue Mondays’: No evidence of affect drop after taking clinical MDMA	4
A Phase 1 single ascending dose study of pure oral harmine in healthy volunteers	4
A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults	4
Brain serotonin, oxytocin, and their interaction: Relevance for eating disorders	4
Should we be leery of being Leary? Concerns about psychedelic use by psychedelic researchers	4
The Afterglow Inventory (AGI): Validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics	4
Predicting clozapine dose required to achieve a therapeutic plasma concentration – A comparison of a population algorithm and three algorithms based on gene variant models	4
Efficacy of rasagiline monotherapy for early Parkinson disease: A systematic review and meta-analysis of randomized controlled trials	4
The cortical silent period in schizophrenia: A systematic review and meta-analysis focusing on disease stage and antipsychotic medication	4
The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration an	4
Low-frequency monitoring for community clozapine initiations: A comparative study relative to standard frequency assessments	4
Rapid and sustained reduction of treatment-resistant PTSD symptoms after intravenous ketamine in a real-world, psychedelic paradigm	4
Compassionate use of esketamine intranasal in patients with severe major depressive disorder resistant to the treatment	4
Cognition-enhancing effect of YL-IPA08, a potent ligand for the translocator protein (18 kDa) in the 5 × FAD transgenic mouse model of Alzheimer’s pathology	4
β-adrenoceptor antagonists and nightmares: A pharmacoepidemiological–pharmacodynamic study	4
Antipsychotic medication in people with intellectual disability and schizophrenia: A 25-year updated systematic review and cross-sectional study	4
To BDZ or not to BDZ? That is the question! Is there reliable scientific evidence for or against using benzodiazepines in the aftermath of potentially traumatic events for the prevention of PTSD? A sy	4
Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience	4
Individual and combined effects of cannabidiol and Δ9-tetrahydrocannabinol on striato-cortical connectivity in the human brain	4
The impact of cannabidiol placebo on amygdala-based neural responses to an acute stressor	4
Repeated administration of L-alanine to mice reduces behavioural despair and increases hippocampal mammalian target of rapamycin signalling: Analysis of gender and metabolic effects	4
MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults	4
Less is more? A review of psilocybin microdosing	4
Association of benzodiazepines, Z-drugs, pregabalin, and melatonin with traffic accidents: A nationwide cohort and case-crossover study in Danish adults	4
Pharmacological treatment for anorexia nervosa: Why are we so skeptical?	3
Cannabinoids: From the brain to society	3
Therapeutic effects of resveratrol on memory deficits in offspring of sleep-deprived rats: Involvement of hippocampal BDNF-TrkB pathways	3
The impact of cannabidiol placebo on responses to an acute stressor: A replication and proof of concept study	3
Effectiveness of vortioxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder in routine clinical practice: A subgroup analysis of the RELIEVE study	3
Aspirin may be more suitable for patients with major depression: Evidence from two-sample Mendelian randomization analysis	3
Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: A phase 1 study in healthy male adults	3
The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder	3
Second International Consensus Study of Antipsychotic Dosing (ICSAD-2)	3
Effects of erythropoietin on cognitive impairment and prefrontal cortex activity across affective disorders: A randomized, double-blinded, placebo-controlled trial	3